CD19 and graft versus host disease: A very satisfactory 90% cumulative survival rate in this specific setting has been found, principally thanks to the absence of severe GvHD and despite a higher incidence of GF after haploidentical TCRαβ/CD19-depleted HSCTs (4/20) compared to HLA-matched HSCTs (4/49).